Mizuho Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $18
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Mizuho analyst Joseph Catanzaro initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target of $18.
Mizuho analyst Joseph Catanzaro initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target of $18.